BeOne Medicines (ONC) Net Cash Flow (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Net Cash Flow of $224.5 million for Q1 2026, up 301.06% year-over-year from $56.0 million in Q1 2025, and down 52.84% quarter-over-quarter from $475.9 million in Q4 2025.
BeOne Medicines (ONC) Net Cash Flow (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Net Cash Flow for 12 consecutive years, with $224.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 301.06% year-over-year to $224.5 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 995.0% YoY), while the FY2025 annual figure was $1.9 billion, up 485.62% from the prior year.
- Net Cash Flow fell to $224.5 million in Q1 2026 per ONC's latest filing, from $475.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $1.3 billion in Q3 2025 and bottomed at -$390.0 million in Q4 2022.
- Historically, Net Cash Flow has averaged $30.6 million across 5 years, with a median of -$37.4 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow sank 815.09% — and 2025, when it surged 2172.2%.
- BeOne Medicines' Net Cash Flow stood at -$390.0 million in 2022, then soared by 116.11% to $62.8 million in 2023, then sank by 136.56% to -$23.0 million in 2024, then soared by 2172.2% to $475.9 million in 2025, then tumbled by 52.84% to $224.5 million in 2026.
- Business Quant data shows ONC's Net Cash Flow at $224.5 million in Q1 2026, $475.9 million in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 407.41 Mn |
| Jun 30, 2026 | 407.41 Mn |
| Mar 31, 2026 | 224.46 Mn |
| Mar 31, 2026 | 224.46 Mn |
| Dec 31, 2025 | 475.94 Mn |
| Dec 31, 2025 | 475.94 Mn |
| Sep 30, 2025 | 1.31 Bn |
| Sep 30, 2025 | 1.31 Bn |
| Jun 30, 2025 | 232.02 Mn |
| Jun 30, 2025 | 232.02 Mn |
| Mar 31, 2025 | -111.64 Mn |
| Mar 31, 2025 | -111.64 Mn |
| Dec 31, 2024 | -22.97 Mn |
| Dec 31, 2024 | -22.97 Mn |
| Sep 30, 2024 | 67.15 Mn |
| Sep 30, 2024 | 67.15 Mn |
| Jun 30, 2024 | -183.60 Mn |
| Jun 30, 2024 | -183.60 Mn |
| Mar 31, 2024 | -356.11 Mn |
| Mar 31, 2024 | -356.11 Mn |